Amgen Inc. (AMGN) — Fair Value Analysis

Base-case fair value (P50): $377.02 · Current price: $374.15 · Verdict: Fairly Valued

The Verdict on AMGN

Amgen Inc (AMGN) currently appears Overvalued based on our Monte Carlo simulations. With a $374.15 market price significantly above our median fair value (P50) of $377.02, the simulations indicate a potential +0.8% downside to its intrinsic value. This suggests that the market is currently pricing in expectations that exceed a probable range of future operational outcomes for AMGN, as modeled across thousands of scenarios. Investors considering AMGN at $374.15 should note this significant premium relative to its analytically derived fair value.

How AMGN stacks up against peers

While Amgen operates within a dynamic sector, its operational and financial health, relative to peers, is categorized as average. This quality tier, combined with the substantial +0.8% difference between $374.15 and the $377.02 median fair value, signals a cautious outlook. An average quality tier suggests that while AMGN is fundamentally sound, it doesn't possess a distinct competitive edge or financial strength that would inherently justify a premium valuation beyond its simulated fair value. The current market price of $374.15 reflects a premium not fully supported by this fundamental assessment.

What this means for investors

For investors, the Overvalued verdict for AMGN, with its $374.15 trading at a +0.8% premium to our $377.02 median fair value, implies elevated risk at current levels. Our Monte Carlo simulations, which model thousands of future scenarios, suggest that the probability-weighted outcomes favor a lower valuation. While a bull case scenario could see AMGN achieve higher targets, the current assessment points to a more probable downside. Conversely, a downside scenario could see prices fall further. To fully understand the distribution of possible outcomes for Amgen, including the full bear and bull case targets, sign up for FairCurve to see the detailed Monte Carlo distribution and track AMGN's fair value as new fundamentals are released.